MacroGenics to receive $15M milestone from Incyte after FDA approval of ZYNYZ

MACROGENICS INC

MacroGenics will receive $15M milestone payment from Incyte after FDA approval of ZYNYZ (retifanlimab-dlwr) for Merkel cell carcinoma.
ZYNYZ, a PD-1 inhibitor, was originally developed by MacroGenics and licensed to Incyte in October 2017.
This marks the third product approval from MacroGenics' pipeline of proprietary or partnered candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.